PAC-1 - CAS# 315183-21-2 r-3 Smiles: CC(C)C[C@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CS)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCSC)NC=O)C(O)=O

Smiles: CC(C)C[C@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CS)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCSC)NC=O)C(O)=O

The pimecrolimus-macrophilin complex prevents the dephosphorylation of the cytoplasmic component of the nuclear factor of activated T cells by inhibiting the action of calcineurin

Formononetin induces apoptosis in PC-3 prostate cancer cells through enhancing the Bax/Bcl-2 ratios and regulating the p38/Akt pathway

5R)-5-ethenyl-1-azabicyclo[2

Chemical Name: [(2S

PAC-1 - CAS# 315183-21-2 r-3 Smiles: CC(C)C[C@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CS)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCSC)NC=O)C(O)=OPAC 1 is known as VO 100 and procaspase activating compound 1; which selectively induces apoptosis, or cell suicide, in cancerous cells. PAC 1 has shown good results in mouse models and is being further evaluated for use in humans. In 2010 a published study showed PAC 1 to be safe to research dogs, and a second study published later that same year reported that a PAC 1 derivative (called S PAC 1) was well tolerated in a small Phase I Clinical Trial of